Dublin, Ireland, 18th July 2008
AGI announces agreement with FDA on key aspects
of Rezular™ ARDIS Phase III programme -- Overall Phase III strategy, design,
primary endpoint confirmed -- -- ARDIS 1 on track to report in H1 2009
--
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal drug products, today
reports on the outcome of a recent meeting with the US Food and Drug Administration
(FDA) in relation to its ARDIS Phase III programme for Rezular™ in diarrhoea-predominant
irritable bowel syndrome (IBS-D) and provides an update on the overall
progress of the ARDIS program. > Learn More
Dublin, Ireland, 21st May 2008
AGI Therapeutics reports key pharmacological and
clinical findings for Rezular™ presented at DDW in San Diego
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal drug products, today
announces the key pharmacology and clinical findings related to Rezular
(arverapamil, AGI-003), which is being developed by the Company as a gastrointestinal-selective
agent for the treatment of diarrhoea-predominant irritable bowel syndrome
(IBS-D), recently presented at Digestive Disease Week (DDW) on Tuesday
20 May, 2008. > Learn More
Dublin, Ireland, 14th May 2008
AGI Therapeutics to present Rezular™ pharmacological
and clinical findings at DDW in San Diego -- 8 a.m. - 5 p.m., Tuesday
20 May, 2008 --
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal drug products, today
announces it will present three poster presentations at Digestive Disease
Week (DDW) at the San Diego Convention Centre on Tuesday 20 May, 2008
.
> Learn More
AGI Therapeutics, plc Financial results for the
twelve months ended 31 December 2007
AGI Therapeutics plc ("AGI" or the "Company"), a speciality
pharmaceutical company focused on gastrointestinal drug products, today
reports audited financial results for the twelve months ended 31 December
2007. > Learn More
Dublin, Ireland, 2nd April 2008
AGI announces key findings of clinical PK study
of arbaclofen (AGI-006)
AGI Therapeutics plc ("AGI" or the "Company") (AIM,
IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal
drug products, today announces the key findings of a clinical study to
assess the pharmacokinetic profile of arbaclofen (AGI-006), which is being
developed for the treatment of gastroparesis, a significant gastric condition
amongst diabetics. > Learn More
Dublin, Ireland, and Columbia, MD, USA, 17 March 2008
AGI Therapeutics announces completion of the optimisation
phase of development of AGI-010
AGI Therapeutics plc ("AGI" or the "Company"), a specialty
pharmaceuticals company focused on gastrointestinal drug products, today
announces the completion of the optimisation phase of development of AGI-010,
a modified release formulation of the proton pump inhibitor drug ("PPI")
omeprazole which utilizes AGI's CHRONAB technology. >
Learn More
Dublin, Ireland, 5th March 2008
AGI Therapeutics to present at Cowen and Company
28th Annual Health Care Conference in Boston
-- 4.45 p.m., Monday 17 March, 2008 --
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that the Company's President of U.S. Operations, Dr. David Young, and Chief Financial Officer, David Kelly, will make a presentation at the Cowen and Company 28th Annual Health Care Conference in Boston. The conference will be held at the Boston Marriott, Copley Place.
AGI will present on Monday 17 March at 4.45 p.m. EST (9.45 p.m. GMT). A copy of the presentation will be available after the event on the AGI website at www.agitherapeutics.com under the "Investors: Publications" tab. > Learn More
Dublin, Ireland, 21st February 2008
Clinical study supports the pharmacokinetic and
safety profile of RezularTM
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal drug products, today
announces the key findings of a clinical study to assess the pharmacokinetic
profile of RezularTM (AGI-003), which is in Phase III clinical trials
for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).
> Learn More
Dublin, Ireland, 5th February 2008
AGI announces first patient dosed in Phase II trial
of AGI-004 in chemotherapy-induced diarrhoea
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal drug products, today
announces that the first patient has been dosed in its Phase II study
of AGI-004 in the treatment of chemotherapy-induced diarrhoea (CID). >
Learn More
Dublin, Ireland, 19th November 2007
AGI Therapeutics to present at 19th Annual Piper
Jaffray Health Care Conference in New York
-- 1.30 p.m., Tuesday 27 November, 2007 --
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), the speciality pharmaceutical company focused on gastrointestinal drug products, today announces that the Company's Chief Executive Officer, Dr. John Devane, will make a presentation at the 19th Annual Piper Jaffray Health Care Conference in New York. > Learn More
Dublin, Ireland, 8th October 2007
AGI's Rezular™ Phase II clinical data to be presented
at American College of Gastroenterology Scientific Meeting
-- 8.30a.m., Wednesday October 17, 2007 --
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the presentation of Phase II clinical results of Rezular, AGI's arverapamil (AGI-003) product, at the American College of Gastroenterology Scientific Meeting being held in Philadelphia. > Learn More
Dublin, Ireland, 3rd October 2007
AGI announces first patient dosed in Phase III
trial of AGI-003, branded as Rezular™, in IBS-D
AGI Therapeutics plc ("AGI" or the "Company") (AIM,
IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal
drug products, today announces that the first patient in its pivotal Phase
III study of AGI-003 (ARDIS) has been dosed. In conjunction with this
important milestone, AGI has branded AGI-003 as 'Rezular™' as it
continues to advance this product into the next phase of its development.
> Learn More
Dublin, Ireland, 26th September 2007
Appointment of Joint Broker and UK Nominated Advisor
AGI Therapeutics plc ("AGI" or "the Company"), a specialty
pharmaceutical company focused on gastrointestinal drug products, announces
the appointment of Piper Jaffray Ltd. as joint broker and UK Nominated
Advisor to the Company.
Davy Stockbrokers will continue as joint broker and IEX advisor to AGI.
> Learn More
Dublin, Ireland, 18th September 2007
AGI Therapeutics, plc reports Interim financial
results for the six months ended 30 June, 2007 and Commencement of enrolment
into Phase III study of arverapamil
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical development company focused on gastrointestinal drug products, today reports interim financial results for the six months ended 30 June, 2007. In addition, today the Company is pleased to report that enrolment has opened into ARDIS-1, the first of three pivotal Phase III studies of arverapamil, (AGI-003), AGI's lead programme for the treatment of diarrhoea-predominant irritable bowel syndrome, (IBS-D), a major unmet medical need. > Learn More
Dublin, Ireland, 12th September 2007
FDA accepts IND filing for arverapamil (AGI-003)
Phase III programme
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) filing for arverapamil (AGI-003), AGI's treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). Based on the FDA's review and comments on the IND, no significant changes are required to the pivotal Phase III study designs and AGI remains on track to initiate two of these studies this year. > Learn More
Dublin, Ireland, 30th August 2007
AGI Therapeutics plc Enters into an exclusive option
agreement to license new pre-clinical compound
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has signed an exclusive option agreement to license certain intellectual property and know-how surrounding a novel prodrug platform for the prokinetic/antiemetic agent, levosulpiride, from Williamsburg Holdings, a US private drug development company. > Learn More
Dublin, Ireland, 11th April 2007
AGI Therapeutics, plc Financial results for the
twelve months ended 31 December 2006
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical
company focused on gastrointestinal drug products, today reports audited
financial results for the twelve months ended 31 December 2006. >
Learn More
(The full annual report is available under Publications in the Investors
section.)
Dublin, Ireland, 11th April 2007
AGI Therapeutics plc FDA approval to file IND for Arverapamil Phase III study
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has concluded a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for arverapamil, (AGI-003), AGI's lead product for irritable bowel syndrome (IBS). > Learn More
Dublin, Ireland, 12th March 2007
AGI Therapeutics plc - Strengthens management team
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of two new Vice Presidents to its management team. > Learn More
Dublin, Ireland, 15th February 2007
AGI Therapeutics plc - Product update and outlook for 2007
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces continued progress on key development programmes and outlines its plans for these programmes in 2007. Following on from the reporting of clinical results on 4 of its products in 2006 and the recent reporting, earlier this month, of clinical results on its other 2 products, AGI is now in a position to map the next key steps in progressing five of the original six products in its pipeline into further clinical development. > Learn More
Dublin, Ireland, 1st February 2007
Preliminary clinical data for mecamylamine (AGI-004) and arbaclofen (AGI-006)
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces preliminary results of Phase II studies for mecamylamine (AGI-004, for functional diarrhoea) and arbaclofen (AGI-006 for functional dyspepsia). The results of these studies follow the reporting last year of positive results for other AGI products in development. > Learn More
Dublin, Ireland, 22nd January 2007
AGI Therapeutics plc appoints strong Medical Advisory Panel.
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of a Medical Advisory Panel of international experts in the field of gastroenterology. > Learn More
Dublin, Ireland, 29 September, 2006
AGI Therapeutics announces preliminary results of phase II trial of espindolol (AGI-001) in irritable bowel syndrome.
AGI Therapeutics plc (AIM, IEX: AGI, "AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of a phase II trial of the Company's espindolol (AGI-001) product candidate for the treatment of irritable bowel syndrome (IBS). > Learn More
Dublin, Ireland, 27th September 2006
AGI Therapeutics plc signs $19 million exclusive license agreement with Axcan Pharma for delayed/controlled release omeprazole.
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has entered into an exclusive license agreement with Axcan Pharma, Inc. ("Axcan") (NASDAQ: AXCA, TSX: AXP) for North American rights to AGI's delayed/controlled release omeprazole formulation, AGI-010. Axcan is a leading marketer of pharmaceutical products for gastrointestinal diseases and disorders in North America and Europe, with revenues in 2005 of over US $250 million. > Learn More
Dublin, Ireland, 7th September 2006
AGI Therapeutics, plc Interim financial results for the six months ended 30 June, 2006.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reports interim financial results for the six months ended 30 June, 2006. > Download results PDF
Dublin, Ireland, 13th July 2006
AGI Therapeutics plc Appoints Chris Blackwell as Non-Executive Director.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of Dr. Chris Blackwell, Chief Executive of Vectura Group plc, to its Board of Directors. > Learn More
Dublin, Ireland, 7th June 2006
AGI Therapeutics Announces Preliminary Results of Phase II Trials for Gastrointestinal Disorders.
AGI Therapeutics plc (AIM, IEX: AGI, "AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of two Phase II trials of its arverapamil (AGI-003) and espindolol (AGI-001) product candidates. > Learn More
Dublin, Ireland, 15th May 2006
AGI Therapeutics plc appoints Dr. David Young as President of US Operations.
AGI Therapeutics plc (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the appointment of David Young, Pharm.D. Ph.D., as President of US Operations and Executive Member of the Board of AGI. The appointment is effective from 5 June 2006. > Learn More
Dublin, Ireland, April 20th 2006
AGI Therapeutics plc announces appointment of Chief Financial Officer.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of Mr. David G. Kelly as director and Chief Financial Officer. Mr. Kelly's appointment will be effective as of 2 May 2006. > Learn More
Dublin, Ireland, April 20th 2006
AGI Therapeutics plc Financial results for the year ended 31 December 2005.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reported the audited financial results for AGI Therapeutics Research Limited, formerly AGI Therapeutics Ltd, for the year ended 31 December 2005. AGI Therapeutics Research Limited is the operating subsidiary of AGI Therapeutics plc which was created as a holding entity prior to the Company's recent flotation. > Learn More
Dublin, Ireland, 29th March 2006
AGI Therapeutics plc reports results of clinical studies for two product candidates.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reported the outcome of a clinical study on its AGI-022 product candidate and preliminary data from a clinical study on its AGI-010 product candidate. Both product candidates are modified release oral formulations of existing drugs used to treat gastrointestinal diseases. > Learn More
Dublin, Ireland, 27 February 2006
AGI Therapeutics plc Admission to trading on AIM and IEX €42.5 Million Placing.
AGI Therapeutics plc ("AGI" or the "Company"), a specialty pharmaceuticals company focused on gastrointestinal drug products, announces that admission to trading will become effective, and dealings in its ordinary shares will commence today on the AIM market of the London Stock Exchange and the IEX market of the Irish Stock Exchange (“Admission”).
> Learn More
